Putnam Investments’s Bio-Rad Laboratories Class A BIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
$10.1M Sell
31,394
-16,512
-34% -$5.18M 0.01% 324
2023
Q3
$17.2M Sell
47,906
-1,618
-3% -$624K 0.03% 231
2023
Q2
$18.8M Sell
49,524
-84,664
-63% -$34.5M 0.03% 217
2023
Q1
$64.3M Buy
134,188
+9,204
+7% +$4.31M 0.1% 138
2022
Q4
$52.6M Buy
124,984
+31,940
+34% +$12.9M 0.09% 142
2022
Q3
$38.8M Buy
93,044
+48,237
+108% +$24M 0.07% 153
2022
Q2
$22.2M Buy
44,807
+8,285
+23% +$4.31M 0.04% 199
2022
Q1
$20.6M Sell
36,522
-35,673
-49% -$21.5M 0.03% 221
2021
Q4
$54.5M Sell
72,195
-6,280
-8% -$4.7M 0.08% 155
2021
Q3
$58.5M Buy
78,475
+296
+0.4% +$222K 0.09% 158
2021
Q2
$50.4M Buy
78,179
+1,060
+1% +$645K 0.08% 167
2021
Q1
$44M Sell
77,119
-18,806
-20% -$11.1M 0.07% 182
2020
Q4
$55.9M Sell
95,925
-6,599
-6% -$3.76M 0.1% 160
2020
Q3
$52.8M Sell
102,524
-8,915
-8% -$4.52M 0.1% 153
2020
Q2
$50.3M Buy
111,439
+62,870
+129% +$27.7M 0.11% 149
2020
Q1
$17M Buy
48,569
+32,990
+212% +$12.1M 0.04% 233
2019
Q4
$5.76M Buy
15,579
+501
+3% +$177K 0.01% 480
2019
Q3
$5.02M Hold
15,078
0.01% 503
2019
Q2
$4.71M Buy
15,078
+600
+4% +$180K 0.01% 531
2019
Q1
$4.42M Sell
14,478
-115,353
-89% -$31.1M 0.01% 542
2018
Q4
$30.1M Sell
129,831
-9,987
-7% -$2.68M 0.08% 195
2018
Q3
$43.8M Buy
139,818
+9,447
+7% +$2.93M 0.09% 174
2018
Q2
$37.6M Sell
130,371
-6,500
-5% -$1.79M 0.09% 195
2018
Q1
$34.2M Sell
136,871
-108,114
-44% -$27.5M 0.08% 210
2017
Q4
$58.5M Buy
244,985
+23,960
+11% +$5.81M 0.13% 159
2017
Q3
$49.1M Buy
221,025
+8,934
+4% +$2.01M 0.11% 162
2017
Q2
$48M Buy
212,091
+118,840
+127% +$25.9M 0.11% 166
2017
Q1
$18.6M Buy
+93,251
New +$18M 0.04% 292
2016
Q3
Sell
-12,885
Closed -$1.84M 1266
2016
Q2
$1.84M Buy
12,885
+150
+1% +$21.4K ﹤0.01% 955
2016
Q1
$1.74M Sell
12,735
-878
-6% -$115K ﹤0.01% 986
2015
Q4
$1.89M Buy
13,613
+991
+8% +$137K ﹤0.01% 991
2015
Q3
$1.7M Buy
+12,622
New +$1.82M ﹤0.01% 1033

Other funds holding BIO

Putnam Investments's BIO Position: Q4 2023 in Review

Putnam Investments reduced its Bio-Rad Laboratories Class A (BIO) stake by 34% in Q4 2023, selling an estimated $5.18M and leaving 31,394 shares worth $10.1M. The position accounts for 0.01% of the portfolio, ranked #324.

Putnam Investments first reported a position in BIO in Q3 2015 and has held it in 32 quarters since. The position peaked at $64.3M in Q1 2023. 483 funds tracked by Wall St. Rank hold BIO as of Q4 2023.

  • Putnam Investments held 31,394 shares of Bio-Rad Laboratories Class A worth $10.1M as of Q4 2023.
  • Putnam Investments sold 16,512 Bio-Rad Laboratories Class A shares in Q4 2023, an estimated $5.18M.
  • Bio-Rad Laboratories Class A made up 0.01% of Putnam Investments's portfolio in Q4 2023, its #324 holding.
  • Putnam Investments first reported a position in Bio-Rad Laboratories Class A in Q3 2015 and has held it in 32 quarters since.
  • Putnam Investments's Bio-Rad Laboratories Class A position peaked at $64.3M in Q1 2023.
  • 483 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2023.

Based on Putnam Investments's 13F filing for Q4 2023, filed 14 Feb 2024.